$ENMI
DH ENCHANTMENT, INC.

2024 Q2 Form 10-K Financial Statement

#000168316824004558 Filed on July 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2024
Revenue $0.00 $0.00 $686.00
YoY Change -100.0% -100.0% -95.46%
Cost Of Revenue $0.00 $0.00 $1.092K
YoY Change -100.0% -100.0% -83.58%
Gross Profit $0.00 $0.00 -$406.00
YoY Change -100.0% -100.0% -104.8%
Gross Profit Margin -59.18%
Selling, General & Admin $38.43K $99.19K $5.518K
YoY Change 1155.06% 110.59% -98.57%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $38.43K $99.19K $144.8K
YoY Change 83.14% 110.59% -62.34%
Operating Profit -$38.43K -$99.19K -$145.2K
YoY Change 79.67% 124.36% -61.39%
Interest Expense $2.717K -$2.740K $10.92K
YoY Change -199.89% 1.86% -212.15%
% of Operating Profit
Other Income/Expense, Net -$2.708K -$10.91K
YoY Change -0.15% 12.09%
Pretax Income -$41.14K -$101.9K -$156.2K
YoY Change 70.69% 82.59% -59.53%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$41.14K -$101.9K -$156.2K
YoY Change 70.69% 82.59% -59.53%
Net Earnings / Revenue -22762.83%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 831.3M shares 831.3M shares 831.3M shares
Diluted Shares Outstanding 831.3M shares 831.3M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.950K $3.200K $3.200K
YoY Change 953.57% -76.28% -76.28%
Cash & Equivalents $2.954K $3.201K $3.200K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $615.00 $613.00 $610.00
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.569K $3.814K $3.810K
YoY Change 257.62% -74.94% -74.97%
LONG-TERM ASSETS
Property, Plant & Equipment $7.646K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.569K $3.814K $3.810K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $3.569K $3.814K $3.810K
YoY Change 257.62% -74.94% -74.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00
YoY Change
Accrued Expenses $452.7K $452.7K $577.1K
YoY Change 0.0% -16.24% 6.78%
Deferred Revenue
YoY Change
Short-Term Debt $134.0K $133.8K $133.8K
YoY Change 0.32% 0.21% 0.21%
Long-Term Debt Due $84.55K $84.28K $84.28K
YoY Change 0.39% 0.24% 0.24%
Total Short-Term Liabilities $1.022M $989.8K $989.8K
YoY Change 20.57% 18.24% 18.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.022M $989.8K $989.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.022M $989.8K $989.8K
YoY Change 20.57% 18.24% 18.24%
SHAREHOLDERS EQUITY
Retained Earnings -$1.855M -$1.814M
YoY Change 10.3% 9.42%
Common Stock $831.3K $831.3K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.018M -$986.0K -$986.0K
YoY Change
Total Liabilities & Shareholders Equity $3.569K $3.814K $3.810K
YoY Change 257.62% -74.94% -74.97%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2024
OPERATING ACTIVITIES
Net Income -$41.14K -$101.9K -$156.2K
YoY Change 70.69% 82.59% -59.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$22.10K -$11.83K -$118.4K
YoY Change -51.88% -48.27% 0.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $12.30K 20.06K $115.6K
YoY Change -62.56% 19960.0% 419.35%
NET CHANGE
Cash From Operating Activities -$22.10K -11.83K -$118.4K
Cash From Investing Activities
Cash From Financing Activities $12.30K 20.06K $115.6K
Net Change In Cash -$397.00 8.230K -$10.57K
YoY Change -96.99% -136.14% -88.99%
FREE CASH FLOW
Cash From Operating Activities -$22.10K -$11.83K -$118.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001300781
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
Unit A, 13/F
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
Gee Luen Factory Building
CY2024 dei Entity Address Address Line3
EntityAddressAddressLine3
316-318 Kwun Tong Road
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Kowloon
CY2024 dei Entity Address Country
EntityAddressCountry
HK
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
00000
CY2024 dei City Area Code
CityAreaCode
852
CY2024 dei Local Phone Number
LocalPhoneNumber
2621 3288
CY2024 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
831310013 shares
CY2023Q3 dei Entity Public Float
EntityPublicFloat
1001790 usd
CY2024 dei Auditor Name
AuditorName
J&S Associate PLT
CY2024 dei Auditor Firm
AuditorFirmId
6743
CY2024 dei Auditor Location
AuditorLocation
Kuala Lumpur, Malaysia
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3201 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13488 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
613 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1700 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
3814 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
15220 usd
CY2024Q1 us-gaap Assets
Assets
3814 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
124400 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
87746 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
452732 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
452732 usd
CY2024Q1 ENMI Amount Due To Director Current
AmountDueToDirectorCurrent
194523 usd
CY2023Q1 ENMI Amount Due To Director Current
AmountDueToDirectorCurrent
78968 usd
CY2024Q1 ENMI Promissory Notes To Director
PromissoryNotesToDirector
84282 usd
CY2023Q1 ENMI Promissory Notes To Director
PromissoryNotesToDirector
84077 usd
CY2024Q1 us-gaap Bank Overdrafts
BankOverdrafts
284 usd
CY2023Q1 us-gaap Bank Overdrafts
BankOverdrafts
0 usd
CY2024Q1 ENMI Note Payable Related Party Current
NotePayableRelatedPartyCurrent
133557 usd
CY2023Q1 ENMI Note Payable Related Party Current
NotePayableRelatedPartyCurrent
133557 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
989778 usd
CY2024Q1 us-gaap Liabilities
Liabilities
989778 usd
CY2023Q1 us-gaap Liabilities
Liabilities
837080 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4400000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4400000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
831310013 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
831310013 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
831310013 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
831310013 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
831310 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
831310 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9652 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1701 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1813962 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1657809 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-985964 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-821860 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3814 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15220 usd
CY2024 us-gaap Revenues
Revenues
686 usd
CY2023 us-gaap Revenues
Revenues
15098 usd
CY2024 us-gaap Cost Of Revenue
CostOfRevenue
1092 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
6646 usd
CY2024 us-gaap Gross Profit
GrossProfit
-406 usd
CY2023 us-gaap Gross Profit
GrossProfit
8452 usd
CY2024 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
-0 usd
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
226366 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5518 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5203 usd
CY2024 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
139315 usd
CY2023 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
153023 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
144833 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
384592 usd
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-145239 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-376140 usd
CY2024 us-gaap Interest And Other Income
InterestAndOtherIncome
9 usd
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
4 usd
CY2024 us-gaap Interest Expense Other
InterestExpenseOther
10923 usd
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
9741 usd
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10914 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9737 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-156153 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-385877 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-156153 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-385877 usd
CY2024 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7951 usd
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1765 usd
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-164104 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-387642 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
831310013 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
831310013 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
831310013 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
831310013 shares
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-156153 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-385877 usd
CY2024 us-gaap Interest Expense
InterestExpense
10923 usd
CY2023 us-gaap Interest Expense
InterestExpense
0 usd
CY2024 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1087 usd
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1700 usd
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-32 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5586 usd
CY2024 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-0 usd
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-4419 usd
CY2024 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
25731 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
259333 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-118380 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-118239 usd
CY2024 ENMI Advance From Director
AdvanceFromDirector
115555 usd
CY2023 ENMI Advance From Director
AdvanceFromDirector
14603 usd
CY2024 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
CY2023 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
57326 usd
CY2024 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
49682 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
115555 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22247 usd
CY2024 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7746 usd
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1916 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10571 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-97908 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13488 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111396 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2917 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13488 usd
CY2024 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-434218 usd
CY2023 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-1765 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-385877 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-821860 usd
CY2024 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-7951 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-156153 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-985964 usd
CY2024 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80B_eus-gaap--NatureOfOperations_z7XyspXIzrQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. <span id="xdx_824_zXSZx53pi9th">DESCRIPTION OF BUSINESS AND ORGANIZATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DH Enchantment, Inc. (the “Company” or “ENMI”) was incorporated in the State of Nevada on July 9, 2004 under the name Amerivestors, Inc. On March 3, 2009, the Company changed its name to Gust Engineering &amp; Speed Productions, Inc. and on February 1, 2011, the Company changed its name to Energy Management International, Inc. Thereafter, on August 11, 2021, the Company further changed its company name to DH Enchantment, Inc., its current name.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, the Company through its subsidiaries, mainly engages with the sale and distribution of COVID-19 rapid antigen tester set. This business was commenced its operation in Hong Kong since October 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 26, 2021, the Company consummated the Share Exchange Transaction (the “Share Exchange”) among DH Investment Group Limited (“DHIG”) and its shareholders. The Company acquired all of the issued and outstanding shares of DHIG from DHIG’s shareholders, in exchange for 100,000 shares of Series B preferred stock, at par value of $0.001. Upon completion of the Share Exchange, DHIG became a 100% owned subsidiary of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Share Exchange, the Company was considered as a shell company due to its nominal assets and limited operation. The transaction will be treated as a recapitalization of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the Share Exchange between the Company and DHIC on July 26, 2021, is a merger of entities under common control that Miss Sally Kin Yi LO is the common director and shareholder of both the Company and DHIG. Under the guidance in ASC 805 for transactions between entities under common control, the assets, liabilities and results of operations, are recognized at their carrying amounts on the date of the Share Exchange, which required retrospective combination of the Company and DHIG for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 29, 2021, the Company authorized and approved the amendment and restatement of our Articles of Incorporation to: (i) change our name to DH Enchantment Inc.; and (ii) amend the powers, rights and designation of the Series A Convertible Preferred Stock as more fully set forth below; and (iii) effectuate a <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20210628__20210629_zFFfHItAV8be" title="Reverse stock split, description">5:1 reverse split</span>, all of which are subject to final authorization by FINRA. The Company also approved the designation of <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20210629__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zzVoH0rArma7" title="Preferred stock, shares authorized">10,000,000</span> shares of Series B Convertible Preferred Stock which took effect immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the amendment, holders of the Series A Convertible Preferred Stock will not be: (i) entitled to receive dividends or other distributions; (ii) vote on matters submitted to a vote of the stockholders; and (iii) able to convert the Series A Convertible Preferred Stock into common stock or any other securities of the corporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20210815__20210816_zYxJEDbuvgek" title="Reverse stock split, description">5 for 1 reverse split</span> of its issued and outstanding shares of common stock. Except for shares authorized, all references to number of shares and per share information have been retroactively adjusted to reflect such split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2024, the Company entered into a Share Exchange Agreement with OLS Asia Corporation, a British Virgin Island corporation (“Buyippee”), and certain Investors pursuant to which the Issuer agreed to issue Twenty Billion (20,000,000,000) shares of its common stock, par value $0.001, to acquire One Thousand (1,000) shares of the OLS Asia Corporation, a British Virgin Island corporation (“OLS”) (representing all of the total issued and outstanding shares of OLS’s Common Stock) held by such Investors. OLS is engaged in the logistics business. As of the date of this report, the agreement is not yet completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Description of subsidiaries</span></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DescriptionOfSubsidiariesTableTextBlock_zSDMaydJvms" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - DESCRIPTION OF BUSINESS AND ORGANIZATION (Details - Description of subsidiaries)"> <tr style="vertical-align: top"> <td><span id="xdx_8B7_zGrs03t3fKbf" style="display: none">Schedule of description of subsidiaries</span> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; width: 20%"><span style="font-size: 10pt">Name</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 18%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Place of incorporation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and kind of</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">legal entity</p></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 21%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal activities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and place of operation</p></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 27%"><span style="font-size: 10pt">Particulars of registered/ paid up share capital</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 10%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">interest held</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238)"> <td><span style="font-size: 10pt"><span id="xdx_907_ecustom--NameOfSubsidiary_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DHInvestmentGroupLimitedMember_zLNK8CPfqjzi" title="Name of subsidiary">DH Investment Group Limited (“DHIG”)</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_909_ecustom--PlaceOfIncorporation_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DHInvestmentGroupLimitedMember_zxxklWjHbFAg" title="Place of incorporation and kind of legal entity">British Virgin Islands</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_90D_ecustom--PrincipalActivities_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DHInvestmentGroupLimitedMember_z2uDmB7duiSe" title="Principal activities and place of operation">Investment holding</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_90B_ecustom--ShareCapital_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DHInvestmentGroupLimitedMember_zEBQHAzOsbW1" title="Particulars of registered/ paid up share capital">100 ordinary shares at par value of US$1</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DHInvestmentGroupLimitedMember_zZH7FqOeBnFi" title="Effective interest held">100</span>%</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238)"> <td><span style="font-size: 10pt"><span id="xdx_90B_ecustom--NameOfSubsidiary_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--HoShunYiLimitedMember_zQDx2kyB1Xvf" title="Name of subsidiary">Ho Shun Yi Limited (“HSYL”)</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_90A_ecustom--PlaceOfIncorporation_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--HoShunYiLimitedMember_zbuG2OdXdeJh" title="Place of incorporation and kind of legal entity">Hong Kong</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_902_ecustom--PrincipalActivities_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--HoShunYiLimitedMember_zqsJIJvVVMZd" title="Principal activities and place of operation">Sale and distribution of COVID-19 rapid antigen tester set</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_903_ecustom--ShareCapital_c20230401__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--HoShunYiLimitedMember_zgR3vbS7zhRc" title="Particulars of registered/ paid up share capital">10,000 ordinary shares for HK$10,000</span></span></td> <td> </td> <td><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--HoShunYiLimitedMember_z1grE04c2SS4" title="Effective interest held">100</span>%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are hereinafter referred to as (the “Company”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
5:1 reverse split
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
5 for 1 reverse split
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zHZOWnl4popk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Wingdings">l</span>   <span id="xdx_86A_z5PfB6IM4pD">Use of estimates and assumptions</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenues and expenses during the years reported. Actual results may differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
CY2023Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-156153 usd
CY2024Q1 ENMI Working Capital
WorkingCapital
-985964 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4400000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4400000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
831310013 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
831310013 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
831310013 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
831310013 shares
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-156153 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-385877 usd
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
831310013 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
831310013 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
831310013 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
831310013 shares
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2024 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
20665 usd
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
40969 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.165 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.165 pure
CY2024 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3410 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6760 usd
CY2024 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
698 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
685 usd
CY2024 ENMI Income Tax Reconciliation Non Taxable Expense
IncomeTaxReconciliationNonTaxableExpense
-1 usd
CY2023 ENMI Income Tax Reconciliation Non Taxable Expense
IncomeTaxReconciliationNonTaxableExpense
0 usd
CY2024 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
2713 usd
CY2023 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
6075 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
195200 usd
CY2023Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
164846 usd
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
195200 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
164846 usd
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001683168-24-004558-index-headers.html Edgar Link pending
0001683168-24-004558-index.html Edgar Link pending
0001683168-24-004558.txt Edgar Link pending
0001683168-24-004558-xbrl.zip Edgar Link pending
dh_ex3101.htm Edgar Link pending
dh_ex3201.htm Edgar Link pending
dh_i10k-033124.htm Edgar Link pending
enmi-20240331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
enmi-20240331_def.xml Edgar Link unprocessable
enmi-20240331_cal.xml Edgar Link unprocessable
enmi-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
enmi-20240331_pre.xml Edgar Link unprocessable
dh_i10k-033124_htm.xml Edgar Link completed